Document Type

Article

Publisher

Elsevier Ireland Ltd

School

School of Medical and Health Sciences

Comments

Originally published as : Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017). Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 404, 62-69. Article found here

Abstract

Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. In melanoma, ctDNA has been shown to have clinical value as an alternative tumour source for the detection clinically targetable mutations for the assessment of response to therapy. This review provides a critical summary of the evidence that gives credence to the utility of ctDNA as a biomarker for monitoring of disease status in advanced melanoma and the steps required for its implementation into clinical settings.

DOI

10.1016/j.canlet.2017.06.030

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Included in

Oncology Commons

Share

 
COinS